Researchers at the University of Cambridge have reported the first human trial of a vaccine whose key antigen component was designed entirely using artificial intelligence.

The experimental vaccine aims to provide broad protection against the sarbecovirus family, which includes the viruses responsible for SARS, COVID-19, and several related animal coronaviruses that could potentially trigger future outbreaks.

Instead of targeting a single viral strain, the AI system analyzed genetic information from thousands of related viruses to identify stable regions that are shared across many variants and are less likely to mutate over time.These conserved features were then used as the basis for the vaccine design.

The vaccine uses DNA technology rather than mRNA, offering potential advantages such as improved stability, easier storage and transportation, and suitability for use in regions with limited cold-chain infrastructure.It can also be delivered without needles through a high-pressure liquid injection system.

In the initial human study, the vaccine was found to be safe and well tolerated, and it successfully stimulated the production of antibodies capable of recognizing multiple sarbecoviruses.

Researchers view this as an important proof of concept demonstrating that AI can assist in designing vaccines intended to remain effective against future variants and related emerging viruses.

However, the immune responses observed were relatively modest, and important questions remain regarding the duration of protection, the need for booster doses, and real-world effectiveness.Larger clinical trials will be required before the vaccine can be considered for widespread use.

While a universal coronavirus vaccine is still years away, the study suggests that AI-assisted vaccine development could become a valuable tool in pandemic preparedness.